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Abstract
Background: Antiretroviral treatment (ART) regimens in HIV patients commonly cause significant lipid elevations,
including increases in both triglycerides and cholesterol. Standard treatments for hypercholesterolemia include the
HMG CoA reductase inhibitors, or “statins.” Because many ART agents and statins share a common metabolic
pathway that uses the cytochrome P450 enzyme system, coadministration of ART with statins could increase statin
plasma levels significantly. The oyster mushroom, Pleurotus ostreatus, has been shown in animal models to
decrease lipid levels - a finding that has been supported by preliminary data in a small human trial.
Methods: To assess the safety and efficacy of P. ostreatus in patients with HIV and ART-induced hyperlipidemia, a
single-arm, open-label, proof-of-concept study of 8 weeks’ duration with a target enrollment of 20 subjects was
conducted. Study patients with ART-induced elevated non-HDL cholesterol levels (> 160 mg/dL) were enrolled.
Participants received packets of freeze-dried P. ostreatus (15 gm/day) to be administered orally for the 8 week trial
period. Lipid levels were drawn every two weeks to assess efficacy. Safety assessments included self-reported
incidence of muscle aches and measurement of liver and muscle enzymes. Mean within-person change in lipid
levels were estimated using generalized estimating equations to account for repeated observations on individuals.
A 30 mg/dL decrease in non-HDL cholesterol was deemed clinically significant.
Results: 126 patients were screened to enroll 25, of which 20 completed the 8-week study. The mean age was
46.4 years (36-60). Patients had a mean 13.7 yrs of HIV infection. Mean non-HDL cholesterol was 204.5 mg/dL at
day 0 and 200.2 mg/dL at day 56 (mean within-person change = -1.70; 95% confidence interval (CI) = -17.4, 14.0).
HDL cholesterol levels increased from 37.8 mg/dL at day 0 to 40.4 mg/dL on day 56 (mean within-person change
= 2.6; 95% CI = -0.1, 5.2). Triglycerides dropped from 336.4 mg/dL on day 0 to 273.4 mg/dL on day 56 (mean
within-person change = -63.0; 95% CI = -120.9, -5.1). Only 3 individuals achieved a sustained clinically significant
(30 mg/dL) decline in non-HDL cholesterol after 8 weeks of therapy. There were no adverse experiences reported
other than patients’ distaste for the preparation. Liver function tests and muscle enzymes were not affected by the
8 weeks of treatment.
Conclusions: Pleurotus ostreatus as administered in this experiment did not lower non-HDL cholesterol in HIV
patients with ART-induced hypercholesterolemia. Small changes in HDL and triglycerides were not of a clinical
magnitude to warrant further study.
Trial Registration: clinicaltrials.gov Identifier: NCT00069524
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Combination antiretroviral therapy (ART) that includes
a protease inhibitor (PI) or non-nucleoside reverse tran-
scriptase inhibitor (NNRTI) is immensely effective in
reducing plasma human immunodeficiency virus type 1
(HIV) levels in most patients, thereby dramatically
decreasing HIV disease progression and mortality.
Unfortunately, ART is associated with a number of
complex metabolic disturbances, including dyslipidemia,
insulin resistance, and body fat redistribution [1,2]. The
dyslipidemia is typically manifested as decreased HDL
cholesterol, increased LDL cholesterol (including small,
dense LDL), and increased total cholesterol. Such values,
associated with increased cardiovascular risk in persons
who are not HIV-infected, also place HIV patients at
risk for premature cardiovascular events [3].
If dietary changes and exercise do not successfully
reverse or arrest lipid changes, the clinician may con-
sider altering the ART regimen; however, both PI and
NNRTI-based therapies have been implicated in ART-
related cholesterol elevations [4]. Even at the low 100
mg dose widely used to “boost” serum concentrations of
other PIs, the PI ritonavir is known to significantly raise
total and LDL cholesterol levels [5]. Hyperlipidemia is
most commonly treated with 3-hydroxy-3methylglutaryl
coenzyme A (HMG CoA) reductase inhibitors, or “sta-
tins.” Using statins concomitantly with ART, though, is
complicated by the fact that statin metabolism is depen-
dant on the same cytochrome P450 isoforms involved in
handling the antiretroviral agents. There have been
cases reported of rhabdomyolysis and death presumably
resulting from statin:PI interactions [6]. Because of the
risk of drug-drug interaction in patients taking ART, a
safer yet effective antihyperlipidemic therapy is desirable.
Dried oyster mushrooms (Pleurotus ostreatus), which
are believed to contain a natural lovastatin-like com-
pound, have been shown to provide significant choles-
terol reductions in animal models. Administering a 5%
dried P. ostreatus powder to male rats, decreased serum
and liver cholesterol 33% and 27%, respectively [7].
Again in male rats, oyster mushrooms reduced HMG-
CoA reductase by more than 30% [8]. The addition of
10% dried fruiting bodies of oyster mushrooms to a
rabbit diet containing 1% cholesterol reduced serum
cholesterol by 65%, lowered both the incidence of ather-
osclerotic plaques and plaque size, and prevented
a t h e r o g e n i cc h a n g e si nt h ea o r t aa n dc o r o n a r ya r t e r i e s
[9]. In a small trial in 5 human subjects, 10-15 grams
per day of a whole dried European strain of Pleurotus
ostreatus mushrooms were ingested over 4 weeks, yield-
ing a 30% reduction in LDL cholesterol levels [10]. The
preclinical evidence and this small human trial, com-
bined with the perceived need to find additional safe
therapies for ART-associated hyperlipidemia, were the
rationale for our pilot study.
Methods
Study Group
The study population was comprised of men and
women 18 years of age or older with documented HIV
infection referred from local physicians and newspaper
advertisements. The study was approved by the Com-
mittee on Human Research at the University of Califor-
nia San Francisco. All participants signed the written
informed consent form. The protocol was originally
designed to include only patients who had been taking
the protease inhibitor combination of lopinavir boosted
by ritonavir (Kaletra); however, to facilitate accrual, the
criteria were ultimately broadened to include those tak-
ing efavirenz (Sustiva) and/or any ritonavir-boosted pro-
tease inhibitor. Participants were required to have been
taking the hyperlipidemia-inducing antiviral therapy for
at least 12 weeks prior to study entry. Necessary labora-
tory values within 30 days prior to enrollment included
serum non-HDL cholesterol levels of 160 mg/dL or
higher and alanine and aspartate transaminase levels
within 2.5 times the upper normal limit. Concurrent
antihyperlipidemic treatment was not allowed, although
prior treatment was not exclusionary. Pregnant and
breastfeeding women were ineligible. Individuals with a
documented history of diabetes mellitus, rhabdomyoly-
sis, or statin-induced myopathy or myalgias were
excluded.
Study Medication
Fungi Perfecti, LLC (Olympia, Washington), produced a
clone of a southern Californian strain of Pleurotus
ostreatus collected from an oak log (Quercus sp.) that
was grown in liquid culture for 3 days, inoculated into
sterilized rice, incubated for two weeks and subsequently
inoculated onto sterilized alder (Alnus rubra)s a w d u s t .
The young mushrooms were harvested, flash frozen,
freeze-dried and “Fitz-milled” into a 20-80 mesh particle
size. The resulting powder was divided into individual
15-gram packets, which subjects were instructed to add
to soup or other hot food once daily for the 8-week
study duration. The packets were maintained by the
Investigational Pharmacy, Positive Health Program, Uni-
versity of California San Francisco, and distributed to
subjects by the study coordinator or the nursing staff at
the San Francisco General Hospital Clinical Research
Center (CRC).
Research Design and Procedures
This was a single-arm, open-label, 8-week proof-of-
concept study of 20 subjects taking efavirenz or a
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men who had elevated non-HDL cholesterol levels
(160 mg/dL or higher). We chose the 8-week study
duration because pharmacologic statins are known to
exert an effect at 4 to 6 weeks, and we theorized that
the lipid-lowering effect of the mushrooms would be
similar or somewhat slower. The efficacy of P. ostrea-
tus mushrooms in this population was investigated by
measuring the effect size, variance, and time to maxi-
mum treatment effect.
Blood was drawn at screening, baseline, and every two
weeks throughout the study to measure fasting lipids
(total cholesterol, HDL cholesterol, direct LDL choles-
terol, VLDL cholesterol, and triglycerides), liver
enzymes, and creatine phosphokinase. A dietary history
was obtained at Days 0, 28, and 56, by a Registered Die-
tician, to assess the specific composition of each sub-
ject’s fat intake as closely as possible. Subjects were
queried at Day 0 and each visit thereafter regarding
adverse experiences, concomitant medications, and
adherence to study medication. Safety measurements
also included serial administration of a myopathy ques-
tionnaire to ascertain the development of any symptoms
suggestive of muscle damage.
Statistical Analysis
The primary objective was to test the hypothesis of
no effect of oyster mushrooms on non-HDL-choles-
terol. A subsequent randomized controlled trial
w o u l db ew o r t hp u r s u i n gi ft h et r u es u c c e s sr a t e ,ς,
estimated by s/n, the proportion of subjects who
responded successfully in the pilot study, was 0.5 or
more. For an individual patient, success was defined
as a 30 mg/dL reduction in non-HDL cholesterol,
comparing day 56 with day 0. With 20 patients, we
h a d8 0 %p o w e rt or e j e c tH 0: ς = 0.5 using a two-
sided 0.05-level z-statistic (i.e., based on z =1 . 9 6 )i f
the true value was < 0.30. Exact 95% confidence
intervals on ς according to the number of successes
observed are reflected in Table 1. Therefore, we
would not proceed with the RCT if we observed a
sustained 30 mg/dL reduction in non-HDL choles-
terol in 5 or fewer individuals.
During the intervention phase of the study, lipid levels
were measured on days 0, 14, 28, 42, and 56. We used
change from day 0 in non-HDL-cholesterol to test the
null hypothesis of no lipid lowering effect of oyster
mushrooms on non-HDL-cholesterol. The data were
summarized as
Cj =n o n− HDLj − non − HDL0for j = 14,...,56 days,
where non-HDL1 represented the lipid level on day 0.
We estimated mean within-person change in non-HDL-
cholesterol at day 14, 28, 42 and 56 using generalized esti-
mating equations to account for repeated measures on
individuals. We described findings by plotting estimated
mean (over subjects) lipid level (non-HDLj) and change in
lipid level (Cj) on each study day. We considered a 30 mg/
dL decrease in non-HDL-cholesterol to be clinically signif-
icant. Hence, for each subject, we identified the first day
on which a 30 mg/dL reduction in non-HDL-cholesterol
was observed (j such that Cj < -30 mg/dL), and obtained a
Kaplan-Meier estimate of this time.
We also measured total cholesterol, HDL-cholesterol,
direct LDL-cholesterol, and triglycerides. We used simi-
lar methods to estimate change in these estimates of
lipid levels.
We report the proportion of patients with increases in
muscle aches, liver enzymes, and CPK levels during the
intervention phase of the study. We also report the
occurrence of myopathy, transaminitis, or rhabdomyoly-
sis in study patients. Adverse events were classified by
stage based on the NIH Division of AIDS toxicity table
for grading adverse events [11].
Results
Patient Characteristics
Of 126 individuals who were screened, 25 subjects were
enrolled (Figure 1). Eighty-three patients failed to meet
screening criteria; 14 did not complete the screen pro-
cess; 4 who were eligible chose not to participate. Five
enrolled subjects discontinued prior to study completion
- 2 prior to day 14 and 3 between days 14 and 28- but
were included in the intent-to-treat analysis. Participants
were mostly male (96%) and Caucasian, non-Latino
(68%), with a mean age of 46.4 years (Table 2). The
mean baseline CD4+ T lymphocyte cell count was 492
cells/mm
3, and on average subjects had been diagnosed
with HIV disease for 13.7 years. Twenty patients were
on boosted protease inhibitor based antiretroviral ther-
apy regimens; 5 were on the non-nucleoside reverse
transcriptase inhibitor, efavirenz, without an accompany-
ing boosted protease inhibitor.
Table 1 Success rate and 95% confidence Intervals based on number of patients out of 20 (ς) who achieve 30 mg/dL
or greater reduction in non-HDL cholesterol
Number of successes, s: 56789 1 0
Estimated success rate, s/16: 0.25 0.30 0.35 0.40 0.45 0.50
95% CI on ς: (0.11, 0.47) (0.15, 0.52) (0.18, 0.57) (0.22, 0.62) (0.26, 0.66) (0.30, 0.70)
Abrams et al. BMC Complementary and Alternative Medicine 2011, 11:60
http://www.biomedcentral.com/1472-6882/11/60
Page 3 of 8Effect on Non-HDL Cholesterol, HDL cholesterol and
triglycerides
At baseline, the mean non-HDL cholesterol was 204.5
mg/dL (normal range 100-199 mg/dL).
Figure 2a plots the serial values through day 56 of the
study. The non-HDL cholesterol was essentially
unchanged by the ingestion of the study preparation
over the 8 weeks of the trial (Table 3). Nine of the parti-
cipants achieved a clinically significant (30 mg/dL or
greater) reduction in non-HDL cholesterol at some time
during study follow-up (Figure 3). All of these patients
were on a boosted PI ART regimen; none of the 5
NNRTI treated participants achieved a reduction of 30
mg/dL in non-HDL cholesterol. However, a clinically
significant reduction was observed in only three patients
at the end of study follow-up.
HDL cholesterol was slightly depressed at baseline to
37.8 mg/dL (normal range 40-57 mg/dL). Figure 2b
shows the 5.8% increase in HDL cholesterol that
resulted after 8 weeks of Pleurotus ostreatus ingestion.
Serum triglycerides fell 18.7% from an average 336.4
mg/dL (normal range less than 149 mg/dL) to 273.4
mg/dL by week 8 (Figure 2c). Models in which we
forced a linear relationship over time did not yield sta-
tistically significant changes in any of our endpoints of
interest (data not shown).
Tolerability and Safety Considerations
Many participants described the mushroom preparation
as difficult to dissolve and hence unpleasant to con-
sume. They described a grittiness and earthy taste that
may have contributed to decreased adherence to the
daily study medication dosing. Other than the distaste,
no significant adverse events were experienced. Safety
laboratory measurements including serum glucose levels,
hepatic transaminases and creatine phosphokinase to
detect subclinical muscle damage remained stable
throughout the eight weeks of the study (Table 3).
Discussion
The particular preparation of freeze-dried Pleurotus
ostreatus that was selected for evaluation in this pilot
study failed to have a sustained effect on non-HDL cho-
lesterol, the primary endpoint. Although 9 participants
achieved the target 30 mg/dL reduction in non-HDL
cholesterol at some time point in the study, only 3 had
this reduction measured at study end. Therefore pursuit
of a larger follow-on study was not deemed warranted
based on our observed results. Of note, the study was
initially designed to examine the effect in patients on a
particular boosted protease inhibitor-based ART regi-
men that had been associated with hyperlipidemia. In
order to assure that we would meet our target enroll-
ment, the eligibility criteria was modified to allow
   PARTICIPANT FLOW DIAGRAM 
         
 
  Assessed for eligibility (n = 126) 
 
 
                  
      
      Excluded (n = 101) 
      Ineligible: 83 
      D i d   n o t   c o m p l e t e   s c r e e n :   1 4  
      D e c l i n e d   t o   p a r t i c i p a t e :   4  
                  Enrolled (n = 25) 
                    
      Discontinued (n = 5) 
      Mushroom palatability: 4 
      P e r s o n a l   r e a s o n s :   1  
               Completed (n = 20) 
Figure 1 Study Participant Flow Sheet.
Table 2 Baseline Characteristics of Enrolled Participants
(N = 25)
Participant Characteristic n Mean %
Years of age 46.4
Male gender 24 96
Race/ethnicity
Caucasian 17 68
African American 4 16
Latino 4 16
Years HIV-infected 13.7
CD4 cell count 494/mm
3
HIV RNA < 75 copies/mL 19 76
Months on HAART 82.3
Target dyslipidemia-inducing agents
lopinavir/ritonavir 15 60
atazanavir/ritonavir 3 12
tipranavir/ritonavir 1 4
fosamprenavir/ritonavir 1 4
efavirenz 5 20
Months on target agent 19.0
History of opportunistic infection 13 52
Cardiac risk factors
Lipodystrophy 13 52
hypertension 7 28
family history of hypertension 9 36
family history of hyperlipidemia 11 44
tobacco smokers 8 32
former smokers 7 28
alcohol users 15 60
former alcohol users 5 20
illicit substance users 14 56
former illicit substance users 7 28
Prior antihyperlipidemic use: 93 6
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Page 4 of 8participants on any boosted protease inhibitor as well as
patients on the NNRTI efavirenz, which had also been
shown to cause lipid perturbations, to be enrolled.
Although the numbers are too small to make any defini-
tive statement, we did note with interest that all of the
non-HDL cholesterol declines of 30 mg/dL or greater
occurred only in the participants on boosted PI regi-
mens who overall experienced a reduction of non-HDL
of 11.2 mg/dL compared to an increase of 13.3 mg/dL
in the 5 efavirenz treated participants. This finding may
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Figure 2 Mean estimated lipid levels (with 95% confidence intervals) associated with use of oyster mushrooms.
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tion could work better with hyperlipidemia secondary to
boosted PI regimens.
Trends suggesting an increase in HDL cholesterol and
a statistically significant decrease in total triglycerides
were noted but were not clinically meaningful. The
mushroom preparation was clinically safe, without
adverse effects other than being deemed distasteful by a
number of study participants. This unpalatability may
have led to decreased adherence to the daily ingestion
of the study preparation which, in turn, may have influ-
enced the results. Carbohydrate analysis by Stamets pre-
viously showed that the same strain of Pleurotus
ostreatus mushrooms grown on sterilized sawdust had
approximately 5% less sugars than the same strain
grown on wheat straw [12]. This decrease in sugar con-
tent may have contributed to the unpalatability reported
by some of the patients. Moreover, it is not known what
Table 3 Mean estimated within-person changes (with 95% confidence intervals) associated with use of oyster
mushrooms*
Day 14
mean change
(95% CI)
Day 28
mean change
(95% CI)
Day 42
mean change
(95% CI)
Day 56
mean change
(95% CI)
Total Cholesterol -9.72
(-20.66, 1.23)
-12.99
(-26.89, 0.91)
4.33
(-11.39, 20.04)
-1.70
(-17.41, 14.02)
Non-HDL -8.06
(-18.72, 2.60)
-10.89
(-23.51, 1.73)
2.06
(-13.24, 17.35)
-4.25
(-19.06, 10.56)
VLDL 2.80
(-4.47, 10.06)
3.47
(-4.08, 11.03)
5.86
(-3.45, 15.16)
-4.07
(-10.73, 2.59)
LDL -8.73
(-20.41, 2.96)
-5.10
(-17.19, 6.99)
2.01
(-12.23, 16.25)
6.89
(-9.29, 23.07)
HDL -1.65
(-3.54, 0.23)
-2.10
(-5.05, 0.85)
2.27
(-0.70, 5.24)
2.55
(-0.07, 5.17)
Triglycerides -22.79
(-102.56, 56.98)
-16.64
(-86.78, 53.50)
-13.64
(-100.67, 73.40)
-62.98
(-120.92, -5.05)
Glucose 0.23
(-5.68, 6.13)
1.90
(-1.77, 5.57)
4.59
(-1.51, 10.68)
-0.12
(-6.25, 6.01)
AST -1.37
(-5.60, 2.86)
-4.62
(-9.65, 0.41)
-2.20
(-7.34, 2.95)
-2.09
(-7.43, 3.26)
ALT -1.31
(-4.22, 1.62)
-3.33
(-6.85, 0.18)
1.56
(-3.29, 6.41)
0.36
(-4.44, 5.15)
* Statistically significant (p < 0.05) changes noted in bold.
Figure 3 Kaplan-Maier estimates of time to 30 mg/dL or greater reduction in non-HDL cholesterol. Legend: ——— Product Limit
Estimate Curve; o o o Censored Observations.
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carbohydrate constitution would have on the outcome
in reducing non-HDL cholesterol. Sterilized sawdust was
chosen over pasteurized straw to assure a product of
greater hygienity, since the colony forming units (cfu) of
microbes on sterilized sawdust was < 10 cfu/gram
whereas the surviving microbes on pasteurized straw
was > 100,000 cfu/gram. The possible transference of
microbes to the mushrooms was a concern given the
study population of immunocompromised patients.
It is also possible that the species used and its pre-
paration may have contributed to our negative results,
although a similar dose of Pleurotus ostreatus was used
in the earlier human trial that reported a 30% reduction
in LDL-cholesterol. It may be, as noted above, that
inoculating Pleurotus onto something other than saw-
dust could potentially increase the lipid-lowering
potency of the preparation. Alternatively, the mush-
rooms being a natural product, the gentler lipid-lower-
ing effect might not have had time to manifest during
our 8-week study. This seems unlikely, however, in that
the prior human study demonstrating a reduction was
of four weeks’ duration.
Other fungal products have already been demon-
strated to have effectiveness in lowering lipid levels. Red
yeast rice is the fermented byproduct of cooked rice in
which a strain of Monascus purpureus is grown. Red
yeast rice has been used in China for centuries as a
medicinal food to promote “blood circulation” in the
Traditional Chinese Medicine sense of the terms. Red
yeast rice contains 9 monacolins, substances with
HMG-Co-A reductase activity. Among the monacolins
identified in red yeast rice is monacolin K, a naturally
occurring form of mevinolin. Placebo controlled clinical
trials have demonstrated a lipid-lowering effect of red
yeast rice preparations in HIV negative patients [13,14].
The preparations are well-tolerated with mild headache
and gastrointestinal distress as adverse effects with no
evidence of impact on liver functions or muscle
enzymes.
A recent trial has demonstrated the effectiveness of
red yeast rice in hyperlipidemic patients intolerant of
conventional statins [15]. To date, no clinical trials of
red yeast rice in HIV patients on antiretroviral therapy
have been reported. In view of the possibility of a mona-
colin interaction with antiviral agents through a cyto-
chrome P450 mechanism, such a study with close safety
monitoring may be warranted in the search for addi-
tional lipid-lowering agents compatible with HIV
therapies.
Conclusions
Pleurotus ostreatus as administered in this experiment
did not lower non-HDL cholesterol in HIV patients
with ART-induced hypercholesterolemia. Small changes
in HDL and triglycerides were not of a clinical magni-
tude to warrant further study.
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